25 Jun 2017 | 7:19 PM
Research Report
Daily

Equity Research Report: Religare Morning Digest

Volatility will hurt intraday and short-term traders the most as we have approached the derivative expiry week. Hence, stock-specific trading approach and limiting position size is the key in current market scenario.
22 Feb 2016 | 07:00 AM

    Religare Morning Digest – Highlights for today
 
Market Outlook for the day -Volatility will hurt intraday and short-term traders the most as we have approached the derivative expiry week. Hence, stock-specific trading approach and limiting position size is the key in current market scenario.
Key Indices – Levels to watch out for the day
INDEX (Spot) RESISTANCE 2 RESISTANCE 1 LTP SUPPORT 1 SUPPORT 2
SENSEX 24110 23900 23709.15 23475 23260
NIFTY 7350 7270 7210.75 7130 7060
NIFTYBANK 14750 14520 14344.20 14175 13980
NIFTYIT 11000 10865 10768.90 10640 10550
News -
  • Cadila Healthcare announced that it has received USFDA approval to market anti-bacterial Doxycycline capsules, USP, 50 mg, 75 mg, and 100 mg.
  • L&T said its construction arm won orders worth Rs 1,404 crore across various business verticals.
  • Suven Life Sciences has been granted a patent each by Australia and Canada for a drug used in the treatment of neuro-degenerative diseases.
 
    Trading/ Investment Ideas
Technical Calls
Company
Name
Recommendation CMP Initiation
Range
Stop
loss
Target Time
Frame
CADILAHC BUY 327.35 318-320 305 345 3-5 Days
RELINFRA SELL MARCH FUT 421.60 430-35 450 395 3-5 Days
 
Derivatives Call
Company
Name
Recommendation CMP Initiation
Price
Stop
loss
Target Time
Frame
INFY BUY MAR 1120 CE 38 38 5 20 3-5 Days
SELL MAR 1140 CE 26.55 27
 
Master Pick (1-2 Months)
Company
Name
Recommendation CMP Initiation
Range
Stop
loss
Target
MARICO BUY 233.05 228-CMP 216 265
To read complete report, please click here
 
Fundamental Picks for delivery (9 Months - 1 Year)
Company
Name
Recommendation CMP Initiation
Range
Target
SMLISUZU BUY 731.70 869.00 1150
JYOTHYLAB BUY 273.35 272.40 330
SUPREMEIND BUY 688.35 699.30 840
Note – For our running recommendations and past performance, please click here
Research Disclaimer